1. Home
  2. NVCR vs CRF Comparison

NVCR vs CRF Comparison

Compare NVCR & CRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • CRF
  • Stock Information
  • Founded
  • NVCR 2000
  • CRF 1973
  • Country
  • NVCR Switzerland
  • CRF United States
  • Employees
  • NVCR N/A
  • CRF N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • CRF Finance/Investors Services
  • Sector
  • NVCR Health Care
  • CRF Finance
  • Exchange
  • NVCR Nasdaq
  • CRF Nasdaq
  • Market Cap
  • NVCR 1.3B
  • CRF 1.2B
  • IPO Year
  • NVCR 2015
  • CRF N/A
  • Fundamental
  • Price
  • NVCR $12.04
  • CRF $7.72
  • Analyst Decision
  • NVCR Buy
  • CRF
  • Analyst Count
  • NVCR 7
  • CRF 0
  • Target Price
  • NVCR $28.64
  • CRF N/A
  • AVG Volume (30 Days)
  • NVCR 1.7M
  • CRF 1.1M
  • Earning Date
  • NVCR 10-30-2025
  • CRF 01-01-0001
  • Dividend Yield
  • NVCR N/A
  • CRF 18.10%
  • EPS Growth
  • NVCR N/A
  • CRF N/A
  • EPS
  • NVCR N/A
  • CRF 1.40
  • Revenue
  • NVCR $642,269,000.00
  • CRF $11,461,786.00
  • Revenue This Year
  • NVCR $9.54
  • CRF N/A
  • Revenue Next Year
  • NVCR $5.70
  • CRF N/A
  • P/E Ratio
  • NVCR N/A
  • CRF $5.38
  • Revenue Growth
  • NVCR 11.17
  • CRF 6.53
  • 52 Week Low
  • NVCR $10.70
  • CRF $5.70
  • 52 Week High
  • NVCR $34.13
  • CRF $9.56
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 47.66
  • CRF 32.91
  • Support Level
  • NVCR $11.09
  • CRF $7.71
  • Resistance Level
  • NVCR $11.63
  • CRF $7.92
  • Average True Range (ATR)
  • NVCR 0.52
  • CRF 0.11
  • MACD
  • NVCR 0.05
  • CRF -0.03
  • Stochastic Oscillator
  • NVCR 86.51
  • CRF 25.56

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About CRF Cornerstone Total Return Fund Inc. (The)

Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.

Share on Social Networks: